Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Denmark

Marie Skłodowska-Curie Action · Running

LINK2CNS Unique and overlapping functions and CNS sites of action for NK2R and LepR signaling

Coordinator
Kobenhavns Universitet, Denmark
Runs
1 September 2026 to 31 August 2029
Status
Running
EU funding
€424k
Total cost
—
Partners
2 organisations in 2 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101209010

What the project is doing

In the project's own words, from its summary on CORDIS.

Metabolic diseases such as obesity and diabetes rank among the primary causes of mortality worldwide. While new incretin-based drugs have made major inroads into the treatment of these diseases, issues with tolerance (including nausea, vomiting, diarrhea; and gastroparesis leading to delayed gastric emptying) threaten to limit the potential long-term compliance and impact of these medications. Thus, it is highly relevant to identify therapeutic targets that reduce appetite without activating aversive circuits or promoting gastroparesis.

Recently, we discovered Neurokinin 2 Receptor (NK2R) as a new pharmacological target for treating obesity. When activated, NK2R improves energy homeostasis by reducing feeding and increasing energy expenditure, resulting in a decrease in body weight via diminished adiposity. Importantly, NK2R agonism controls appetite without activating CNS circuits that induce aversive effects and, unlike incretin-based therapies, can compensate for leptin-controlled feeding in leptin-deficient hyperphagic mice.

This suggests that NK2R agonism mimics leptin for the control of feeding and likely engages leptin-regulated neural circuits. During this fellowship, I will define unique and overlapping functions and CNS sites of action for NK2R and Leptin Receptor signaling using proprietary pharmacological NK2R agonists, molecular genetic neuroscience techniques, metabolic phenotyping, and transcriptomics. This will not only expand our understanding of the promising mode-of-action of NK2R agonists but also has the potential to reveal new mechanisms of central homeostatic control that can be exploited pharmacologically for the treatment of cardiometabolic diseases.

The combination of the expertise of my host labs and my experience will ensure the successful completion of the fellowship and uniquely positions me as an expert in both peripheral and central control of energy homeostasis and strengthens my transferable skills to start my independent career.

Topics

Who is involved

OrganisationCityCountryRole
Kobenhavns UniversitetKobenhavnDenmarkCoordinator
Regents of the University of MichiganAnn ArborUnited StatesAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI